Korean J Urol.  2013 Apr;54(4):271-273.

Lung Metastasis of Ta Bladder Cancer: A Case Report and Literature Review

• Sano T
• Hamada S
• Haitani T
• Nakashima
• Kajita Y
• Shichiri Y

Abstract

A 66-year-old man with a history of multiple transurethral resections for recurrent bladder tumors, staged as Ta according to the International Union Against Cancer staging guidelines, presented with a complaint of dry cough. A round nodule with a diameter of 7.5 cm was detected in the lung by chest computed tomography, and a video-assisted thoracoscopic lobectomy was performed. Pulmonary metastasis of recurrent bladder cancer was diagnosed by immunohistochemistry staining for the urothelium-specific protein uroplakin Ia. Subsequently, 2 cycles of systemic chemotherapy were administered. Two and a half years after treatment, no recurrence of pulmonary lesions has been detected. A combination of complete resection of pulmonary lesions and systemic chemotherapy may result in a good prognosis for patients with non-muscle-invasive bladder cancer.

Keyword

Indirect fluorescent antibody technique; Solitary pulmonary nodule; Urinary bladder neoplasms

MeSH Terms

Cough
Fluorescent Antibody Technique, Indirect
Humans
Immunohistochemistry
Lung
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Recurrence
Solitary Pulmonary Nodule
Thorax
Urinary Bladder
Urinary Bladder Neoplasms
Uroplakin Ia
Uroplakin Ia

Figure

• 

  FIG. 1 A computed tomography scan showing a large mass in the upper lobe of the right lung.

• 

  FIG. 2 Uroplakin Ia (UP-Ia) staining in bladder urothelial carcinoma and lung metasitasis (×200; bar=200 µm). (A) Bladder urothelial carcinoma shows diffuse cytoplasmic staining and umbrella cells show strong immunoreaction for UP-Ia. (B) Moderate positive immunostaining in lung metastasis.

Reference

1. Kageyama S, Yoshiki T, Isono T, Tanaka T, Kim CJ, Yuasa T, et al. High expression of human Uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res. 2002. 93:523–531.

2. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000. 18:3068–3077.

3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006. 49:466–477.

4. Matthews PN, Madden M, Bidgood KA, Fisher C. The clinicopathological features of metastatic superficial papillary bladder cancer. J Urol. 1984. 132:904–906.

5. Kakehi Y, Nishio Y, Hashimura T, Takeuchi H, Yoshida O. Clinicopathological analysis on invasion and metastasis in superficial bladder cancer. Hinyokika Kiyo. 1992. 38:783–788.

6. Zennami K, Yamada Y, Nakamura K, Aoki S, Taki T, Honda N. Solitary brain metastasis from pT1, G3 bladder cancer. Int J Urol. 2008. 15:96–98.

7. Seymour JE, Malin JM Jr, Pierce JM Jr. Late metastases of a superficial transitional cell carcinoma of the bladder: report of a case. J Urol. 1972. 108:277–278.

8. Koh KB, Rogawski K, Smith PH. Cavitating pulmonary metastases from superficial transitional cell carcinoma of urinary bladder: case report. Scand J Urol Nephrol. 1994. 28:201–202.

9. Dougherty DW, Gonsorcik VK, Harpster LE, Trussell JC, Drabick JJ. Superficial bladder cancer metastatic to the lungs: Two case reports and review of the literature. Urology. 2009. 73:210e3–e5.